Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
Caris Life Sciences, Phoenix, Arizona.
Mol Cancer Ther. 2020 Dec;19(12):2634-2640. doi: 10.1158/1535-7163.MCT-20-0318. Epub 2020 Oct 9.
Goblet cell carcinoid (GCC) is a distinct subtype of appendiceal neoplasm that exhibits unique clinical and pathologic features. We aimed to reveal the molecular profiles of GCC compared with other appendiceal tumors, such as adenocarcinomas and neuroendocrine tumors. A total of 495 appendiceal tumor samples (53 GCCs, 428 adenocarcinomas, and 14 neuroendocrine tumors) were tested with next-generation sequencing (NGS) on a 592-gene panel and IHC. Microsatellite instability (MSI)/mismatch repair (MMR) status was tested with a combination of NGS, IHC, and fragment analyses. Tumor mutational burden (TMB) was evaluated by NGS, and PD-L1 expression was tested by IHC (SP142). The most prevalent mutated genes within GCCs were (24.0%), (15.4%), (9.4%), and (7.5%). Pathway-specific alterations were dominantly observed in cell cycle, MAPK, epigenetic, and TGFβ signaling pathways. GCCs as compared with adenocarcinomas exhibited significantly lower mutation rates in , and , and significantly higher mutation rates in , and GCCs as compared with neuroendocrine tumors showed significantly lower mutation rates in , and In GCCs, MSI high/MMR deficient, TMB high (≥17 mutations/Mb), and PD-L1 expression were seen in 0.0%, 0.0%, and 2.0% of tumors, respectively. No significant differences were observed in any immunotherapy-related markers examined when compared with adenocarcinomas and neuroendocrine tumors. In conclusion, GCCs had considerably distinct mutational profiles compared with appendiceal adenocarcinomas and neuroendocrine tumors. Understanding these molecular characteristics may be critical for the development of novel and more effective treatment strategies for GCC.
杯状细胞类癌(Goblet Cell Carcinoid,GCC)是一种独特的阑尾肿瘤亚型,具有独特的临床和病理特征。我们旨在揭示 GCC 与其他阑尾肿瘤(如腺癌和神经内分泌肿瘤)相比的分子特征。总共对 495 个阑尾肿瘤样本(53 个 GCC、428 个腺癌和 14 个神经内分泌肿瘤)进行了下一代测序(NGS)在 592 个基因面板和免疫组化上进行检测。微卫星不稳定性(MSI)/错配修复(MMR)状态通过 NGS、IHC 和片段分析的组合进行测试。通过 NGS 评估肿瘤突变负担(TMB),并通过 IHC(SP142)测试 PD-L1 表达。GCC 中最常见的突变基因是 (24.0%)、 (15.4%)、 (9.4%)和 (7.5%)。细胞周期、MAPK、表观遗传和 TGFβ 信号通路中主要观察到特定途径的改变。与腺癌相比,GCC 的 、 和 突变率显著降低, 、 和 突变率显著升高。与神经内分泌肿瘤相比,GCC 的 、 和 突变率显著降低, 、 和 突变率显著升高。在 GCC 中,MSI 高/MMR 缺陷、TMB 高(≥17 突变/Mb)和 PD-L1 表达分别在 0.0%、0.0%和 2.0%的肿瘤中出现。与腺癌和神经内分泌肿瘤相比,在任何免疫治疗相关标志物的检查中均未观察到显著差异。总之,GCC 与阑尾腺癌和神经内分泌肿瘤相比,其突变谱有很大的不同。了解这些分子特征对于开发针对 GCC 的新型、更有效的治疗策略可能至关重要。